ATyr Historical Balance Sheet
| LIFE Stock | USD 2.00 0.07 3.63% |
Trend analysis of aTyr Pharma balance sheet accounts such as Total Stockholder Equity of 86.1 M provides information on ATyr Pharma's total assets, liabilities, and equity, which is the actual value of aTyr Pharma to its prevalent stockholders. By breaking down trends over time using ATyr Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining aTyr Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether aTyr Pharma is a good buy for the upcoming year.
ATyr Pharma Inventory |
|
ATyr |
About ATyr Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of aTyr Pharma at a specified time, usually calculated after every quarter, six months, or one year. ATyr Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ATyr Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ATyr currently owns. An asset can also be divided into two categories, current and non-current.
ATyr Pharma Balance Sheet Chart
ATyr Pharma Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how aTyr Pharma uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, ATyr Pharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Cash And Short Term Investments is expected to grow to about 156.6 M, whereas Total Current Liabilities is forecasted to decline to about 15.6 M. Add Fundamental
Total Assets
Total assets refers to the total amount of ATyr Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in aTyr Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on ATyr Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of aTyr Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents ATyr Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of aTyr Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most accounts from ATyr Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into aTyr Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.At present, ATyr Pharma's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Cash And Short Term Investments is expected to grow to about 156.6 M, whereas Total Current Liabilities is forecasted to decline to about 15.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 4.0M | 9.9M | 23.1M | 40.5M | Total Assets | 115.5M | 95.8M | 122.1M | 116.0M |
ATyr Pharma balance sheet Correlations
Click cells to compare fundamentals
ATyr Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ATyr Pharma balance sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 36.2M | 38.7M | 115.5M | 95.8M | 122.1M | 116.0M | |
| Other Current Liab | 2.4M | 3.6M | 4.0M | 9.9M | 23.1M | 40.5M | |
| Total Current Liabilities | 12.9M | 5.9M | 6.0M | 13.9M | 16.4M | 15.6M | |
| Total Stockholder Equity | 21.0M | 31.5M | 109.1M | 71.3M | 90.7M | 86.1M | |
| Net Tangible Assets | 21.2M | 31.7M | 109.1M | 71.5M | 82.2M | 86.3M | |
| Retained Earnings | (322.3M) | (338.5M) | (372.3M) | (417.6M) | (468.0M) | (444.6M) | |
| Accounts Payable | 847K | 1.4M | 1.0M | 3.1M | 3.5M | 3.4M | |
| Cash | 9.2M | 17.0M | 2.3M | 10.0M | 22.5M | 21.4M | |
| Non Current Assets Total | 4.3M | 3.0M | 1.8M | 14.7M | 19.1M | 18.1M | |
| Non Currrent Assets Other | 172K | 213K | 158K | (22K) | 131K | 124.5K | |
| Cash And Short Term Investments | 31.1M | 31.7M | 107.9M | 69.3M | 98.2M | 156.6M | |
| Common Stock Total Equity | 30K | 31K | 4K | 11K | 9.9K | 9.4K | |
| Short Term Investments | 21.9M | 14.7M | 105.6M | 56.2M | 75.6M | 42.2M | |
| Liabilities And Stockholders Equity | 36.2M | 38.7M | 115.5M | 95.8M | 122.1M | 116.0M | |
| Non Current Liabilities Total | 2.2M | 1.4M | 398K | 10.6M | 15.2M | 14.4M | |
| Other Current Assets | 781K | 2.0M | 5.4M | 3.0M | 2.4M | 2.3M | |
| Other Stockholder Equity | 343.4M | 370.0M | 481.7M | 489.3M | 558.7M | 289.5M | |
| Total Liab | 15.2M | 7.2M | 6.4M | 24.5M | 31.6M | 30.0M | |
| Total Current Assets | 31.9M | 35.7M | 113.7M | 81.1M | 103.0M | 97.8M | |
| Short Term Debt | 9.5M | 861K | 980K | 894K | 1.3M | 1.3M | |
| Common Stock | 4K | 11K | 28K | 29K | 63K | 59.9K | |
| Property Plant Equipment | 4.1M | 3.0M | 1.8M | 11.6M | 10.4M | 9.9M | |
| Other Assets | 172K | 1K | 158K | 3.4M | 1.0 | 0.95 | |
| Accumulated Other Comprehensive Income | (40K) | (43K) | (263K) | (433K) | (74K) | (70.3K) | |
| Short Long Term Debt Total | 3.0M | 2.2M | 1.4M | 11.5M | 15.1M | 10.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether aTyr Pharma is a strong investment it is important to analyze ATyr Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ATyr Pharma's future performance. For an informed investment choice regarding ATyr Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in aTyr Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. For information on how to trade ATyr Stock refer to our How to Trade ATyr Stock guide.Note that the aTyr Pharma information on this page should be used as a complementary analysis to other ATyr Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for ATyr Stock analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is ATyr Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.29) | Return On Equity (0.56) |
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.